Plutux
$4.86
-0.61%
2026-09-04 12:07:19 EDT-$0.03
헬스케어
생명공학
NASDAQ
활발히 거래 중

ImageneBio, Inc.는 면역학적, 자가면역 및 염증성 질환 환자를 위한 치료제를 개발하는 임상 단계의 바이오제약 회사입니다. 주요 제품 후보에는 활성화된 T 세포의 OX40 ...

주가 흐름

$4.86
-0.61%-$0.03
고가
저가
52주 최고-48.7%
거래량비
간격
범위63m
거래량SMA5SMA10
ImageneBio Inc (NASDAQ: IMA) is a clinical-stage biotechnology company dedicated to developing novel therapeutics for patients with immunological, autoimmune, and inflammatory diseases. The company was originally founded as Inmagene in 2019 and became public via a reverse merger with Ikena Oncology in July 2025, forming ImageneBio. Headquartered in San Diego, ...ImageneBio Inc (NASDAQ: IMA) is a clinical-stage biotechnology company dedicated to developing novel therapeutics for patients with immunological, autoimmune, and inflammatory diseases. The company was originally founded as Inmagene in 2019 and became public via a reverse merger with Ikena Oncology in July 2025, forming ImageneBio. Headquartered in San Diego, California, the company is led by CEO Kristin Yarema, with co-founders Yanina Grant and Jonathan Wang. The company's primary focus is on advancing its lead asset, IMG-007, a non-depleting anti-OX40 monoclonal antibody designed to modulate T-cell responses in inflammatory diseases. IMG-007 is currently in Phase 2b clinical trials for atopic dermatitis, with topline data expected in Q4 2025. The company is also exploring other indications and pipeline candidates. As a clinical-stage biotech, ImageneBio has no approved products or revenue, and its financials reflect significant R&D investment. As of the latest data, the company has a market cap of approximately $63.3 million, with a cash position of about $8.42 per share and a strong current ratio of 21.47, indicating ample liquidity. The company employs 15 full-time employees and operates with a lean structure. ImageneBio aims to address significant unmet medical needs in immunology and inflammation, positioning itself as a potential leader in anti-OX40 therapies.
설립
2019
직원 수
18
CEO
Kristin Yarema
정식 명칭
ImageneBio Inc
섹터
헬스케어
산업
생명공학
ROE
-38.99%
시가총액
$0.06B
유동비율
21.47
WACC
6.94%
ROIC
-39.87%

연락처 정보

858 345 6265
12526 High Bluff Drive, Suite 345, San Diego, CA 92130, 샌디에이고, CA 92130

관련 종목Biotechnology

전체 미국 주식 보기

Plutux는 투자자문업자가 아닙니다. 시장 데이터와 AI가 생성한 분석은 정보 제공 및 교육 목적일 뿐 투자 자문이 아닙니다. 면책 조항

© Plutux Technology Limited 2026